IASIS PHARMA is pleased to announce the launch of Sitagliptin/IASIS 25 mg/mL in the pharmaceutical form of an oral solution.

This is a new, innovative, and unique formulation belonging to the class of DPP-4i. It is an R&D and manufacturing product by IASIS PHARMA HELLAS.

Each 1 mL of Sitagliptin/IASIS oral solution contains sitagliptin hydrochloride monohydrate, equivalent to 25 mg of sitagliptin.

Superior to Solid Dosage Forms & Optimal Adhearence:

Sitagliptin/IASIS 25 mg/mL oral solution represents an excellent therapeutic option, specifically designed for patients facing swallowing difficulties (dysphagia). It provides patients with type 2 diabetes mellitus with rapid bioavailability, high dosing accuracy, ease of titration, and optimal treatment compliance.

Dosage and Administration :

The recommended dose is 100 mg (corresponding to 4 mL of oral solution) of sitagliptin once daily, taken with or without food. The solution is slightly opalescent, off-white, featuring a pleasant wild berry aroma.

Suitable for Special Patient Populations (Renal Impairment):

According to the Summary of Product Characteristics (SPC), no dose adjustment is required for patients with mild or moderate renal impairment (GFR ≥ 45 mL/min). For patients with GFR ≥ 30 to < 45 mL/min, the dose is adjusted to 50 mg (2 mL of solution) once daily, while for severe renal impairment (GFR < 30 mL/min), the dose is 25 mg (1 mL of solution) once daily.

Packaging & Ease of Use:

Sitagliptin/IASIS is supplied in an amber glass bottle. To ensure maximum dosing accuracy and convenience during administration, the pack includes a 5 mL graduated plastic syringe in 0.5 mL increments.

Anargyrios and Korgialenios School, Spetses.

IASIS PHARMA successfully participated in the 9^th Panhellenic Conference of S.S.D.V.A.D., titled “SKIN DISEASES 2026: PAST, PRESENT & FUTURE”, held on May 28-30, 2026, at the Anargyrios and Korgialenios School on Spetses island.

The conference was organized by the Society for the Study of Dermatological, Venereological & Allergological Diseases (S.S.D.V.A.D.), chaired by Mr. D. Rigopoulos, Professor Emeritus of Dermatology – Venereology at the NKUA School of Medicine.

At the IASIS PHARMA exhibition booth, the following products were presented:

• Isotroin^® / Isotretinoin: This well-established formulation has been enriched with the new and unique 30mg strength, which complements the existing range of dosages (10mg, 20mg & 40mg). Isotroin® is indicated for severe forms of acne resistant to systemic antibiotics and topical therapy.
• Combi^®: A combination of fluprednidene (1mg) + miconazole (20mg) in cream form (50gr), indicated for Inflammatory Dermatomycoses.
• Modiwart^® / Imiquimod (12.5mg/sachet): An innovative immunomodulator indicated for External Genital Warts, Superficial Basal Cell Carcinomas, and Actinic Keratoses.
• Mastiha var. Chia Cutaneous Regenerative Gel: Since 2015, Chios Mastic has been officially recognized by the European Medicines Agency (EMA) as an Herbal Medicinal Product, with the indication: Skin Inflammations & Healing of Minor Skin Wounds (cutaneous use). It is used for minor skin inflammations and as an aid in healing minor wounds. (Concentration: Each ml of gel contains 10% lyophilized resin of natural Chios mastic Pistacia lentiscus, excipients. 30ml packaging).

Athenaeum Intercontinental, Αthens.

IASIS PHARMA participated in the 21^st Panhellenic Conference of Dermatology & Venereology «The Skin Enigma» held on 2 to 5 April 2026, at the Athenaeum Intercontinental hotel.

The conference was organized by the Hellenic Society of Dermatology and Venereology.

Many Dermatologists attended the congress and had the chance to visit IASIS PHARMA exhibition stand and got informed of 4 important IASIS Dermatological products:

• Isotroin^®/ Isotretinoin, indicated for severe forms of Acne that are resistant to treatment with systemically administered antibiotics and topical therapy. Isotroin® 30mg is added to the range of the other Isotroin® strengths (10mg, 20mg & 40mg).
• Combi^®, a combination of fluprednidene (1mg) + miconazole (20mg) cream for the treatment of Inflammatory Dermatomycoses.
• Modiwart^®/Ιmiquimod (12,5mg/sach), an innovative modifier of the immune response system indicated for the treatment of: External Genital Warts, Superficial Basal Cell Carcinomas and Aktinic Keratoses.
• Mastiha var. Chia Αναπλαστικό & Καταπραϋντικό Gel (30ml), which is used in minor skin inflammations and as an aid in the healing of microtraumas, because since 2015, Chios mastic gum has been officially recognized by the European Medicines Agency (EMA) as Herbal Medicine with the indication: Skin Inflammation & Skin Wound Healing (cutaneous use).

The Skin Enigma, 2026

Divani Caravel Hotel, Athens.

IASIS PHARMA participated at the “24th PANHELLENIC DIABETES CONGRESS”, held in Athens, at the Divani Caravel Hotel, showing its active interest in Diabetes Mellitus disease. Moreover, IASIS PHARMA is about to invest significantly in T2DM by launching original products in oral liquid forms.

The conference took place from March 18 to 21, 2026, with the participation of more than 1.500 Health Care Professionals.

IASIS PHARMA participated in the event with an exhibition stand, where experts had the opportunity to visit and learn about the range of high-quality proprietary pharmaceuticals available from the company.

At IASIS PHARMA exhibition stand, the following products were presented:

• RosuZet^®: Fixed-dose combination of Rosuvastatin & Ezetimibe, in a single dosage form, in packages of  30 f.c. tabs available in the full spectrum of strengths: (Rosuvastatin / Ezetimibe) 5 / 10mg, 10 / 10mg, 20 / 10mg, 40 / 10mg.
• Rami–Amlo^®: a fixed-dose combination of Ramipril & Amlodipine in a single dosage form, in packages of 28 capsules, available in 4 strengths: (Ramipril / Amlodipine) 5mg / 5mg,  5mg / 10mg, 10mg / 5mg, 10mg / 10mg.
• Rami–Amlo plus^®: also an original fixed-dose combination of Ramipril – Amlodipine –Hydrochlorothiazide, which is available in packages of 30 capsules, in a wide range of strengths: (Ramipril / Amlodipine / Hydrochlorothiazide) 5 mg / 5 mg / 12,5 mg, 5 mg / 5 mg / 25 mg, 10 mg / 5 mg / 25 mg, 10 mg / 10 mg / 25 mg.
• – Glucofree^®: Each film-coated tablet contains 850 mg Metformin hydrochloride, equivalent to 662,9 mg metformin respectively (box of 60 f.c. tabs).
  –  Glucoplus^®: Each film-coated tablet contains 1000 mg Metformin hydrochloride, equivalent to 780mg Metformin respectively (box of 60 f.c. tabs).
• MAG-IASIS^®: the first uniquely effective combination of 1193.57 mg Magnesium citrate & 667.56 mg Magnesium aspartate, equivalent to 243 mg Magnesium, indicated for magnesium deficiency, in the form of 40 effervescent tablets.

THE MET, Thessaloniki.

IASIS PHARMA participated at the “Panhellenic Seminars of the Cardiology Working Groups”, held in Thessaloniki, at the Met Hotel, from February 12 to 14, 2026.

In IASIS PHARMA exhibition stand, the following products were presented:

• RosuZet^®: New Product Launching. Fixed-dose combination of Rosuvastatin & Ezetimibe, in a single dosage form, in packages of 30 f.c. tabs available in the full spectrum of strengths: (Rosuvastatin / Ezetimibe)

5 / 10mg,
10 / 10mg,
20 / 10mg,
40 / 10mg.

• Rami–Amlo^®: an original fixed-dose combination of Ramipril & Amlodipine in a single dosage form, in packages of 28 capsules, available in 4 strengths:
  5mg/5mg,
  5mg/10mg,
  10mg/5mg,
  10mg/10mg.
• Rami–Amlo plus^®: also an original fixed-dose combination of Ramipril – Amlodipine –Hydrochlorothiazide, which is available in packages of 30 capsules, in a wide range of strengths:
  (Ramipril / Amlodipine / Hydrochlorothiazide)
  5 mg/5 mg/12,5 mg,
  5 mg/5 mg/25 mg,
  10 mg/5 mg/25 mg,
  10 mg/10 mg/25 mg
• MAG-IASIS^®: the first uniquely effective combination of 1193.57 mg Magnesium citrate & 667.56 mg Magnesium aspartate, equivalent to 243 mg Magnesium, indicated for magnesium deficiency, in the form of 40 effervescent tablets.
• Licepler^®: (Eplerenone) available in packages of 30 film-coated tablets, in 25mg and 50mg strengths.

Eugenides Foundation (Planetarium), Athens

During 12 – 13/12/2025, the 24th Dermatological Conference “Skin, Kaleidoscope of Health” took place at Planetarium/Athens.

Greek Dermatologists who attended the conference visited IASIS PHARMA exhibition stand to get informed of the IASIS Dermatological products:

• Isotroin^®/ Isotretinoin, (at the new & unique 30mg dosage) indicated for severe forms of Acne that are resistant to treatment with systemically administered antibiotics and topical therapy. Isotroin^® 30mg is added to the range of the other Isotroin® strengths (namely 10mg, 20mg & 40mg).
• Combi^®, a combination of fluprednidene (1mg) + miconazole (20mg) cream for the treatment of Inflammatory Dermatomycoses.
• Modiwart^®/Ιmiquimod (12,5mg/sach), an innovative modifier of the immune response system indicated for the treatment of: External Genital Warts, Superficial Basal Cell Carcinomas and Aktinic Keratoses.
• Mastiha var. Chia Cutaneous Regenerative Gel (30ml), which is used in minor skin inflammations and as an aid in the healing of microtraumas, because since 2015, Chios mastic gum has been officially recognized by the European Medicines Agency (EMA) as Herbal Medicine with the indication: Skin Inflammation & Skin Wound Healing (cutaneous use).

Divani Caravel Hotel/ Athens.

IASIS PHARMA participated in the 11^th Panhellenic Conference of Working Groups organized by the Hellenic Atherosclerosis Society. The conference was held from 05 to 06/12/2025, at the Divani Caravel Hotel in Athens, with the participation of many Healthcare Professionals.

Participants had the opportunity to learn more about the high-quality pharmaceutical products available from the company.

At IASIS PHARMA exhibition stand, the following products were displayed:

• RosuZet^®: Fixed-dose combination of Rosuvastatin & Ezetimibe, in a single dosage form, in packages of 30 f.c. tabs available in the full spectrum of strengths:5/10mg, 10/10mg, 20/10mg and 40/10mg.
• Rami–Amlo^®: a fixed-dose combination of Ramipril & Amlodipine in a single dosage form, in packages of 28 capsules, available in 4 strengths:
  5mg/5mg,
  5mg/10mg,
  10mg/5mg,
  10mg/10mg.
• Rami–Amlo plus^®, also an original fixed-dose combination of Ramipril – Amlodipine –Hydrochlorothiazide, which is available in packages of 30 capsules, in a wide range of strengths: 5mg/5mg/12,5 mg, 5 mg/5 mg/25 mg, 10 mg/5 mg/25 mg, 10 mg/10 mg/25 mg.

Athenaeum InterContinental, Athens

During 19 – 23/11 2025, at Athenaeum InterContinental / Athens, the Hellenic Dermatology & Venereology Society together with the Dermatology & Venereology Society of Cyprus organized the 3^rd Panhellenic Conference of Dermatology and Venerology.

Greek Dermatologists who attended the congress visited IASIS PHARMA exhibition stand to get informed of the IASIS Dermatological products:

• Isotroin^®/ Isotretinoin, indicated for severe forms of Acne that are resistant to treatment with systemically administered antibiotics and topical therapy. Isotroin^® 30mg is added to the range of the other Isotroin® strengths (10mg, 20mg & 40mg).
• Combi^®, a combination of fluprednidene (1mg) + miconazole (20mg) cream for the treatment of Inflammatory Dermatomycoses.
• Modiwart^®/Ιmiquimod (12,5mg/sach), an innovative modifier of the immune response system indicated for the treatment of: External Genital Warts, Superficial Basal Cell Carcinomas and Aktinic Keratoses.
• Mastiha var. Chia Cutaneous Regenerative Gel (30ml), which is used in minor skin inflammations and as an aid in the healing of microtraumas, because since 2015, Chios mastic gum has been officially recognized by the European Medicines Agency (EMA) as Herbal Medicine with the indication: Skin Inflammation & Skin Wound Healing (cutaneous use).

Makedonia Palace, Thessaloniki

IASIS PHARMA participated in the “25^th PANHELLENIC CONGRESS OF HYPERTENSION” which was held from 06/11 to 08/11 2025, at the Makedonia Palace Hotel/Thessaloniki.

The conference was organized by the Hellenic Society of Hypertension (HSH).

IASIS PHARMA presented at its exhibition stand the following products:

• RosuZet^®: New Product Launching. Fixed-dose combination of Rosuvastatin & Ezetimibe, in a single dosage form, in packages of 30 f.c. tabs available in the full spectrum of strengths: 5 / 10mg, 10 / 10mg, 20 / 10mg, 40 / 10mg
• Rami–Amlo^®: the original fixed dose combination of angiotensin-converting enzyme inhibitors with calcium channel blockers. Therapeutic indication, substitution therapy in patients whose blood pressure is adequately controlled with ramipril and amlodipine simultaneously at the same dose level. (Box of 28 caps, Ramipril / Amlodipine: 5mg / 5mg, 5mg / 10mg, 10mg / 5mg, 10mg / 10mg).
• Rami–Amlo plus^®: the original, fixed dose combination of Ramipril – Amlodipine – Hydrochlorothiazide, indicated for the treatment of Hypertension. (Box of 30 caps, Ramipril / Amlodipine / Hydrochlorothiazide: 5 mg / 5 mg / 12,5 mg, 5 mg / 5 mg / 25 mg, 10 mg / 5 mg / 25 mg, 10 mg / 10 mg / 25 mg).
• Licepler^®: Licepler is specifically indicated for the reduction of risk of cardiovascular death in people with heart failure and left ventricular dysfunction ≤40% after a recent acute myocardial infarction, in combination with standard therapies and as treatment against hypertension. (Box of 30 tabs at 25mg & 50mg).

Conference Center of the University of Patras, City of Patras

IASIS PHARMA participated with great success for another year in the 45^th  Pan-Hellenic Gastroenterology Conference, which was held under the auspices of the Hellenic Gastroenterological Society (EGE), at the Conference Center of the University of Patras, on 10/23/25 – 10/26/2025.

IASIS PHARMA presented the unique herbal medicine   Mastiha var. Chia, in two forms:

1. Mastiha var. Chiacaps. Capsules against functional dyspepsia, with the active substance natural Chios mastic (Pistacia lentiscus L., resin), 350mg/cap.
2. CHIOS MASTIHA POWDER. Against functional dyspepsia, with the active substance Pistacia lentiscus L., resin at 1080 mg / sachet. Package of 15 sachets.

Previously, the lack of a monograph on the analysis of the components of Chios mastic resin, had created a serious gap in the control of the quality of the product itself and its by-products.

Recently, IASIS PHARMA Research and Development department, in collaboration with the School of Pharmacy, of the University of Athens, elaborated the Development of Analytical Methods for the Qualitative Determination of the Active Ingredients of Chios mastic, as well as the Quantitative Determination of its main Components, as the only reliable analytical approach for Chios mastic quality control, along with the confrontation of any potential case of merchantry fraud.

Consequently, IASIS PHARMA, using the relevant technology and the suitable scientific “know-how”, offers Updated Data, Important Scientific Facts & the Latest Developments, regarding this unique herbal product that has a wide range of beneficial, but mainly therapeutical indications for human beings.